1. Pink Sheet
  2. >>Legislation

Drug Product Hopping Bill Should Specify Anti-Competitive 'Window', Congress Advised

 
• By Brenda Sandburg

House bill in the works to deter brand product switches should specify what behavior would be unacceptable, legal experts testify at congressional hearing.

Kangaroos-2-hopping

As Rep. Jan Schakowsky, D-Ill, plans to introduce a bill targeted at brand manufacturer product hopping, legal experts offered advice on how to assure it is not too broad or vague as to interfere with normal business practices.

Schakowsky announced that she was working on the legislation at a 19 September hearing of the House Energy and Commerce Subcommittee on Consumer Protection and Commerce

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.